顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > スボレキサント原料薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）

スボレキサント原料薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）

Suvorexant API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
  • レポートID：
    384604
  • 発表時期：
    2026-01-19
  • レポート形式：
    PDF
  • 産業カテゴリー：
    化学及び材料
  • レポート言語：
    英語、日本語
  • ページ数：
    135
  • 発行会社（調査会社）：
    QYResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界のスボレキサント原料薬市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からスボレキサント原料薬市場を分析し、需要構造と成長特性を明確化します。
スボレキサント原料薬市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、スボレキサント原料薬に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要スボレキサント原料薬市場の統計
2025年世界市場規模：百万米ドル
2026年世界市場規模：百万米ドル
2032年予測市場規模：百万米ドル
2026–2032年予測期間CAGR：
本レポートはスボレキサント原料薬市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
スボレキサント原料薬市場の主要企業には以下が含まれます：
Merck
Biophore
Metrochem
Alembic Pharmaceuticals
Bajaj Healthcare
DEAFARMA
LifeFirst Pharma
Saptagir Laboratories
SMS Pharmaceuticals
Viatris
Zydus Lifesciences
Axplora
Apino Pharma
Conscientia Industrial
BSAZ Biotech
Sandoo Pharmaceutical 

製品別
Industrial Grade (98%-99.0%)
Pharmaceutical Grade (99.0%-99.5%)
High Purity Grade (Greater Than 99.5%) 

アプリケーション別
Insomnia
Others 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
スボレキサント原料薬市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
スボレキサント原料薬市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にスボレキサント原料薬市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にスボレキサント原料薬市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、スボレキサント原料薬市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、スボレキサント原料薬市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
スボレキサント原料薬市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●スボレキサント原料薬市場の全体像と成長見通し
スボレキサント原料薬市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がスボレキサント原料薬市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
スボレキサント原料薬産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
スボレキサント原料薬市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からスボレキサント原料薬市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
スボレキサント原料薬市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
スボレキサント原料薬市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
title

Description

The global market for Suvorexant API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.

The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Suvorexant API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Suvorexant, sold under the brand name Belsomra, is an orexin antagonist drug used to treat insomnia. It is specifically designed to treat insomnia characterized by difficulty falling or staying asleep in adults, helping to fall asleep faster, stay asleep longer, wake up less often in the middle of the night, and achieve better quality sleep.

The Suvorexant API industry chain consists of upstream fine chemicals and key pharmaceutical intermediates, midstream API synthesis and crystal form control, and downstream formulation companies and end-user applications. Downstream demand is concentrated in formulation companies producing novel mechanism drugs for insomnia and large prescription drug retailers. These companies leverage their clinical, brand, and channel advantages to promote the use of Suvoresin formulations in hospitals and specialized sleep medicine institutions. Within the downstream structure, the growth rate of demand from formulation companies far exceeds that of upstream capacity expansion, making it the core driving force for industry scale expansion. Simultaneously, hospital systems, internet healthcare, and chain pharmacies have improved prescription accessibility, resulting in a stable upward trend in API demand.

The development trend of Suvoresin API is driven by the increasing global demand for insomnia treatment, the substitution of non-benzodiazepine drugs, policy support for low-dependency drugs, and the continued recognition of innovative mechanisms. With the increasing specialization of sleep medicine and patients' growing concern for safety, dual orexin receptor antagonist products maintain rapid growth in many countries. Downstream formulation companies' continuous expansion of indications and accelerated international registration will further increase their procurement of APIs. Obstacles remain, including complex active pharmaceutical ingredient (API) synthesis routes, high costs, relatively concentrated supply of core intermediates, difficulty in controlling crystal form consistency, long market entry cycles in some markets, and slow shifts in physician prescribing habits. Awareness of these drugs in emerging markets such as Southeast Asia and the Middle East also needs improvement, resulting in uneven regional penetration.

In 2024, the production volume of Suvorexant API was 448 kg, with an average price of US$22,400/kg and a gross profit margin typically ranging from 45% to 60%.

This report provides a comprehensive view of the global market for Suvorexant API, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Suvorexant API market size, estimations, and forecasts are presented in terms of sales volume (kg) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Suvorexant API.

Market Segmentation
By Company
    Merck
    Biophore
    Metrochem
    Alembic Pharmaceuticals
    Bajaj Healthcare
    DEAFARMA
    LifeFirst Pharma
    Saptagir Laboratories
    SMS Pharmaceuticals
    Viatris
    Zydus Lifesciences
    Axplora
    Apino Pharma
    Conscientia Industrial
    BSAZ Biotech
    Sandoo Pharmaceutical

Segment by Type
    Industrial Grade (98%-99.0%)
    Pharmaceutical Grade (99.0%-99.5%)
    High Purity Grade (Greater Than 99.5%)

Segment by Synthesis Method
    Fragment Splicing Method
    Linear Synthesis Method

Segment by Drug Registration Classification
    Original Drug
    Generic Drug

Segment by Application
    Insomnia
    Others

By Region
    North America
    Europe
    China
    Japan

Consumption by Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the Suvorexant API manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Suvorexant API sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Suvorexant API sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
title

Table of Contents

1 Market Overview
    1.1 Suvorexant API Product Introduction
    1.2 Global Suvorexant API Market Size Forecast
        1.2.1 Global Suvorexant API Sales Value (2021–2032)
        1.2.2 Global Suvorexant API Sales Volume (2021–2032)
        1.2.3 Global Suvorexant API Sales Price (2021–2032)
    1.3 Suvorexant API Market Trends & Drivers
        1.3.1 Suvorexant API Industry Trends
        1.3.2 Suvorexant API Market Drivers & Opportunities
        1.3.3 Suvorexant API Market Challenges
        1.3.4 Suvorexant API Market Restraints
        1.3.5 Impact of U.S. Tariffs
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered
2 Competitive Analysis by Company
    2.1 Global Suvorexant API Players Revenue Ranking (2025)
    2.2 Global Suvorexant API Revenue by Company (2021–2026)
    2.3 Global Suvorexant API Sales Volume Ranking of Players (2025)
    2.4 Global Suvorexant API Sales Volume by Company (2021–2026)
    2.5 Global Suvorexant API Average Price by Company (2021–2026)
    2.6 Key Manufacturers Suvorexant API Manufacturing Base and Headquarters
    2.7 Key Manufacturers Suvorexant API Product Offerings
    2.8 Key Manufacturers Start of Mass Production of Suvorexant API
    2.9 Suvorexant API Market Competitive Analysis
        2.9.1 Suvorexant API Market Concentration Rate (2021–2026)
        2.9.2 Global 5 and 10 Largest Manufacturers by Suvorexant API Revenue in 2025
        2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Suvorexant API revenue, 2025
    2.10 Mergers & Acquisitions and Expansion
3 Segmentation Suvorexant API Market Classification
    3.1 Introduction by Type
        3.1.1 Industrial Grade (98%-99.0%)
        3.1.2 Pharmaceutical Grade (99.0%-99.5%)
        3.1.3 High Purity Grade (Greater Than 99.5%)
        3.1.4 Global Suvorexant API Sales Value by Type
            3.1.4.1 Global Suvorexant API Sales Value by Type (2021 vs 2025 vs 2032)
            3.1.4.2 Global Suvorexant API Sales Value, by Type (2021–2032)
            3.1.4.3 Global Suvorexant API Sales Value, by Type (%), 2021–2032
        3.1.5 Global Suvorexant API Sales Volume by Type
            3.1.5.1 Global Suvorexant API Sales Volume by Type (2021 vs 2025 vs 2032)
            3.1.5.2 Global Suvorexant API Sales Volume, by Type (2021–2032)
            3.1.5.3 Global Suvorexant API Sales Volume, by Type (%), 2021–2032
        3.1.6 Global Suvorexant API Average Price by Type (2021–2032)
    3.2 Introduction by Synthesis Method
        3.2.1 Fragment Splicing Method
        3.2.2 Linear Synthesis Method
        3.2.3 Global Suvorexant API Sales Value by Synthesis Method
            3.2.3.1 Global Suvorexant API Sales Value by Synthesis Method (2021 vs 2025 vs 2032)
            3.2.3.2 Global Suvorexant API Sales Value, by Synthesis Method (2021–2032)
            3.2.3.3 Global Suvorexant API Sales Value, by Synthesis Method (%), 2021–2032
        3.2.4 Global Suvorexant API Sales Volume by Synthesis Method
            3.2.4.1 Global Suvorexant API Sales Volume by Synthesis Method (2021 vs 2025 vs 2032)
            3.2.4.2 Global Suvorexant API Sales Volume, by Synthesis Method (2021–2032)
            3.2.4.3 Global Suvorexant API Sales Volume, by Synthesis Method (%), 2021–2032
        3.2.5 Global Suvorexant API Average Price by Synthesis Method (2021–2032)
    3.3 Introduction by Drug Registration Classification
        3.3.1 Original Drug
        3.3.2 Generic Drug
        3.3.3 Global Suvorexant API Sales Value by Drug Registration Classification
            3.3.3.1 Global Suvorexant API Sales Value by Drug Registration Classification (2021 vs 2025 vs 2032)
            3.3.3.2 Global Suvorexant API Sales Value, by Drug Registration Classification (2021–2032)
            3.3.3.3 Global Suvorexant API Sales Value, by Drug Registration Classification (%), 2021–2032
        3.3.4 Global Suvorexant API Sales Volume by Drug Registration Classification
            3.3.4.1 Global Suvorexant API Sales Volume by Drug Registration Classification (2021 vs 2025 vs 2032)
            3.3.4.2 Global Suvorexant API Sales Volume, by Drug Registration Classification (2021–2032)
            3.3.4.3 Global Suvorexant API Sales Volume, by Drug Registration Classification (%), 2021–2032
        3.3.5 Global Suvorexant API Average Price by Drug Registration Classification (2021–2032)
4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Insomnia
        4.1.2 Others
    4.2 Global Suvorexant API Sales Value by Application
        4.2.1 Global Suvorexant API Sales Value by Application (2021 vs 2025 vs 2032)
        4.2.2 Global Suvorexant API Sales Value, by Application (2021–2032)
        4.2.3 Global Suvorexant API Sales Value, by Application (%), 2021–2032
    4.3 Global Suvorexant API Sales Volume by Application
        4.3.1 Global Suvorexant API Sales Volume by Application (2021 vs 2025 vs 2032)
        4.3.2 Global Suvorexant API Sales Volume, by Application (2021–2032)
        4.3.3 Global Suvorexant API Sales Volume, by Application (%), 2021–2032
    4.4 Global Suvorexant API Average Price by Application (2021–2032)
5 Segmentation by Region
    5.1 Global Suvorexant API Sales Value by Region
        5.1.1 Global Suvorexant API Sales Value by Region: 2021 vs 2025 vs 2032
        5.1.2 Global Suvorexant API Sales Value by Region (2021–2026)
        5.1.3 Global Suvorexant API Sales Value by Region (2027–2032)
        5.1.4 Global Suvorexant API Sales Value by Region (%), 2021–2032
    5.2 Global Suvorexant API Sales Volume by Region
        5.2.1 Global Suvorexant API Sales Volume by Region: 2021 vs 2025 vs 2032
        5.2.2 Global Suvorexant API Sales Volume by Region (2021–2026)
        5.2.3 Global Suvorexant API Sales Volume by Region (2027–2032)
        5.2.4 Global Suvorexant API Sales Volume by Region (%), 2021–2032
    5.3 Global Suvorexant API Average Price by Region (2021–2032)
    5.4 North America
        5.4.1 North America Suvorexant API Sales Value, 2021–2032
        5.4.2 North America Suvorexant API Sales Value by Country (%), 2025 vs 2032
    5.5 Europe
        5.5.1 Europe Suvorexant API Sales Value, 2021–2032
        5.5.2 Europe Suvorexant API Sales Value by Country (%), 2025 vs 2032
    5.6 Asia Pacific
        5.6.1 Asia Pacific Suvorexant API Sales Value, 2021–2032
        5.6.2 Asia Pacific Suvorexant API Sales Value by Region (%), 2025 vs 2032
    5.7 South America
        5.7.1 South America Suvorexant API Sales Value, 2021–2032
        5.7.2 South America Suvorexant API Sales Value by Country (%), 2025 vs 2032
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Suvorexant API Sales Value, 2021–2032
        5.8.2 Middle East & Africa Suvorexant API Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Suvorexant API Sales Value Growth Trends, 2021 vs 2025 vs 2032
    6.2 Key Countries/Regions Suvorexant API Sales Value and Sales Volume
        6.2.1 Key Countries/Regions Suvorexant API Sales Value, 2021–2032
        6.2.2 Key Countries/Regions Suvorexant API Sales Volume, 2021–2032
    6.3 United States
        6.3.1 United States Suvorexant API Sales Value, 2021–2032
        6.3.2 United States Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.3.3 United States Suvorexant API Sales Value by Application, 2025 vs 2032
    6.4 Europe
        6.4.1 Europe Suvorexant API Sales Value, 2021–2032
        6.4.2 Europe Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.4.3 Europe Suvorexant API Sales Value by Application, 2025 vs 2032
    6.5 China
        6.5.1 China Suvorexant API Sales Value, 2021–2032
        6.5.2 China Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.5.3 China Suvorexant API Sales Value by Application, 2025 vs 2032
    6.6 Japan
        6.6.1 Japan Suvorexant API Sales Value, 2021–2032
        6.6.2 Japan Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.6.3 Japan Suvorexant API Sales Value by Application, 2025 vs 2032
    6.7 South Korea
        6.7.1 South Korea Suvorexant API Sales Value, 2021–2032
        6.7.2 South Korea Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.7.3 South Korea Suvorexant API Sales Value by Application, 2025 vs 2032
    6.8 Southeast Asia
        6.8.1 Southeast Asia Suvorexant API Sales Value, 2021–2032
        6.8.2 Southeast Asia Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.8.3 Southeast Asia Suvorexant API Sales Value by Application, 2025 vs 2032
    6.9 India
        6.9.1 India Suvorexant API Sales Value, 2021–2032
        6.9.2 India Suvorexant API Sales Value by Type (%), 2025 vs 2032
        6.9.3 India Suvorexant API Sales Value by Application, 2025 vs 2032
7 Company Profiles
    7.1 Merck
        7.1.1 Merck Company Information
        7.1.2 Merck Introduction and Business Overview
        7.1.3 Merck Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.1.4 Merck Suvorexant API Product Offerings
        7.1.5 Merck Recent Developments
    7.2 Biophore
        7.2.1 Biophore Company Information
        7.2.2 Biophore Introduction and Business Overview
        7.2.3 Biophore Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.2.4 Biophore Suvorexant API Product Offerings
        7.2.5 Biophore Recent Developments
    7.3 Metrochem
        7.3.1 Metrochem Company Information
        7.3.2 Metrochem Introduction and Business Overview
        7.3.3 Metrochem Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.3.4 Metrochem Suvorexant API Product Offerings
        7.3.5 Metrochem Recent Developments
    7.4 Alembic Pharmaceuticals
        7.4.1 Alembic Pharmaceuticals Company Information
        7.4.2 Alembic Pharmaceuticals Introduction and Business Overview
        7.4.3 Alembic Pharmaceuticals Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.4.4 Alembic Pharmaceuticals Suvorexant API Product Offerings
        7.4.5 Alembic Pharmaceuticals Recent Developments
    7.5 Bajaj Healthcare
        7.5.1 Bajaj Healthcare Company Information
        7.5.2 Bajaj Healthcare Introduction and Business Overview
        7.5.3 Bajaj Healthcare Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.5.4 Bajaj Healthcare Suvorexant API Product Offerings
        7.5.5 Bajaj Healthcare Recent Developments
    7.6 DEAFARMA
        7.6.1 DEAFARMA Company Information
        7.6.2 DEAFARMA Introduction and Business Overview
        7.6.3 DEAFARMA Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.6.4 DEAFARMA Suvorexant API Product Offerings
        7.6.5 DEAFARMA Recent Developments
    7.7 LifeFirst Pharma
        7.7.1 LifeFirst Pharma Company Information
        7.7.2 LifeFirst Pharma Introduction and Business Overview
        7.7.3 LifeFirst Pharma Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.7.4 LifeFirst Pharma Suvorexant API Product Offerings
        7.7.5 LifeFirst Pharma Recent Developments
    7.8 Saptagir Laboratories
        7.8.1 Saptagir Laboratories Company Information
        7.8.2 Saptagir Laboratories Introduction and Business Overview
        7.8.3 Saptagir Laboratories Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.8.4 Saptagir Laboratories Suvorexant API Product Offerings
        7.8.5 Saptagir Laboratories Recent Developments
    7.9 SMS Pharmaceuticals
        7.9.1 SMS Pharmaceuticals Company Information
        7.9.2 SMS Pharmaceuticals Introduction and Business Overview
        7.9.3 SMS Pharmaceuticals Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.9.4 SMS Pharmaceuticals Suvorexant API Product Offerings
        7.9.5 SMS Pharmaceuticals Recent Developments
    7.10 Viatris
        7.10.1 Viatris Company Information
        7.10.2 Viatris Introduction and Business Overview
        7.10.3 Viatris Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.10.4 Viatris Suvorexant API Product Offerings
        7.10.5 Viatris Recent Developments
    7.11 Zydus Lifesciences
        7.11.1 Zydus Lifesciences Company Information
        7.11.2 Zydus Lifesciences Introduction and Business Overview
        7.11.3 Zydus Lifesciences Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.11.4 Zydus Lifesciences Suvorexant API Product Offerings
        7.11.5 Zydus Lifesciences Recent Developments
    7.12 Axplora
        7.12.1 Axplora Company Information
        7.12.2 Axplora Introduction and Business Overview
        7.12.3 Axplora Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.12.4 Axplora Suvorexant API Product Offerings
        7.12.5 Axplora Recent Developments
    7.13 Apino Pharma
        7.13.1 Apino Pharma Company Information
        7.13.2 Apino Pharma Introduction and Business Overview
        7.13.3 Apino Pharma Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.13.4 Apino Pharma Suvorexant API Product Offerings
        7.13.5 Apino Pharma Recent Developments
    7.14 Conscientia Industrial
        7.14.1 Conscientia Industrial Company Information
        7.14.2 Conscientia Industrial Introduction and Business Overview
        7.14.3 Conscientia Industrial Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.14.4 Conscientia Industrial Suvorexant API Product Offerings
        7.14.5 Conscientia Industrial Recent Developments
    7.15 BSAZ Biotech
        7.15.1 BSAZ Biotech Company Information
        7.15.2 BSAZ Biotech Introduction and Business Overview
        7.15.3 BSAZ Biotech Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.15.4 BSAZ Biotech Suvorexant API Product Offerings
        7.15.5 BSAZ Biotech Recent Developments
    7.16 Sandoo Pharmaceutical
        7.16.1 Sandoo Pharmaceutical Company Information
        7.16.2 Sandoo Pharmaceutical Introduction and Business Overview
        7.16.3 Sandoo Pharmaceutical Suvorexant API Sales, Revenue, Price and Gross Margin (2021–2026)
        7.16.4 Sandoo Pharmaceutical Suvorexant API Product Offerings
        7.16.5 Sandoo Pharmaceutical Recent Developments
8 Industry Chain Analysis
    8.1 Suvorexant API Industrial Chain
    8.2 Suvorexant API Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Key Suppliers of Raw Materials
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customer Analysis)
    8.5 Sales Model and Sales Channelss
        8.5.1 Suvorexant API Sales Model
        8.5.2 Sales Channels
        8.5.3 Suvorexant API Distributors
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer
title

Table of Figures

List of Tables
 Table 1. Suvorexant API Market Trends
 Table 2. Suvorexant API Market Drivers & Opportunities
 Table 3. Suvorexant API Market Challenges
 Table 4. Suvorexant API Market Restraints
 Table 5. Global Suvorexant API Revenue by Company (US$ Million), 2021–2026
 Table 6. Global Suvorexant API Revenue Market Share by Company (2021–2026)
 Table 7. Global Suvorexant API Sales Volume by Company (kg), 2021–2026
 Table 8. Global Suvorexant API Sales Volume Market Share by Company (2021–2026)
 Table 9. Global Market Suvorexant API Price by Company (US$/kg), 2021–2026
 Table 10. Key Manufacturers Suvorexant API Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Suvorexant API Product Type
 Table 12. Key Manufacturers Start of Mass Production of Suvorexant API
 Table 13. Global Suvorexant API Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on Suvorexant API revenue, 2025
 Table 15. Mergers & Acquisitions and Expansion Plans
 Table 16. Global Suvorexant API Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
 Table 17. Global Suvorexant API Sales Value by Type (US$ Million), 2021–2026
 Table 18. Global Suvorexant API Sales Value by Type (US$ Million), 2027–2032
 Table 19. Global Suvorexant API Sales Market Share in Value by Type (2021–2026)
 Table 20. Global Suvorexant API Sales Market Share in Value by Type (2027–2032)
 Table 21. Global Suvorexant API Sales Volume by Type: 2021 vs 2025 vs 2032 (kg)
 Table 22. Global Suvorexant API Sales Volume by Type (kg), 2021–2026
 Table 23. Global Suvorexant API Sales Volume by Type (kg), 2027–2032
 Table 24. Global Suvorexant API Sales Market Share in Volume by Type (2021–2026)
 Table 25. Global Suvorexant API Sales Market Share in Volume by Type (2027–2032)
 Table 26. Global Suvorexant API Price by Type (US$/kg), 2021–2026
 Table 27. Global Suvorexant API Price by Type (US$/kg), 2027–2032
 Table 28. Global Suvorexant API Sales Value by Synthesis Method: 2021 vs 2025 vs 2032 (US$ Million)
 Table 29. Global Suvorexant API Sales Value by Synthesis Method (US$ Million), 2021–2026
 Table 30. Global Suvorexant API Sales Value by Synthesis Method (US$ Million), 2027–2032
 Table 31. Global Suvorexant API Sales Market Share in Value by Synthesis Method (2021–2026)
 Table 32. Global Suvorexant API Sales Market Share in Value by Synthesis Method (2027–2032)
 Table 33. Global Suvorexant API Sales Volume by Synthesis Method: 2021 vs 2025 vs 2032 (kg)
 Table 34. Global Suvorexant API Sales Volume by Synthesis Method (kg), 2021–2026
 Table 35. Global Suvorexant API Sales Volume by Synthesis Method (kg), 2027–2032
 Table 36. Global Suvorexant API Sales Market Share in Volume by Synthesis Method (2021–2026)
 Table 37. Global Suvorexant API Sales Market Share in Volume by Synthesis Method (2027–2032)
 Table 38. Global Suvorexant API Price by Synthesis Method (US$/kg), 2021–2026
 Table 39. Global Suvorexant API Price by Synthesis Method (US$/kg), 2027–2032
 Table 40. Global Suvorexant API Sales Value by Drug Registration Classification: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Global Suvorexant API Sales Value by Drug Registration Classification (US$ Million), 2021–2026
 Table 42. Global Suvorexant API Sales Value by Drug Registration Classification (US$ Million), 2027–2032
 Table 43. Global Suvorexant API Sales Market Share in Value by Drug Registration Classification (2021–2026)
 Table 44. Global Suvorexant API Sales Market Share in Value by Drug Registration Classification (2027–2032)
 Table 45. Global Suvorexant API Sales Volume by Drug Registration Classification: 2021 vs 2025 vs 2032 (kg)
 Table 46. Global Suvorexant API Sales Volume by Drug Registration Classification (kg), 2021–2026
 Table 47. Global Suvorexant API Sales Volume by Drug Registration Classification (kg), 2027–2032
 Table 48. Global Suvorexant API Sales Market Share in Volume by Drug Registration Classification (2021–2026)
 Table 49. Global Suvorexant API Sales Market Share in Volume by Drug Registration Classification (2027–2032)
 Table 50. Global Suvorexant API Price by Drug Registration Classification (US$/kg), 2021–2026
 Table 51. Global Suvorexant API Price by Drug Registration Classification (US$/kg), 2027–2032
 Table 52. Global Suvorexant API Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
 Table 53. Global Suvorexant API Sales Value by Application (US$ Million), 2021–2026
 Table 54. Global Suvorexant API Sales Value by Application (US$ Million), 2027–2032
 Table 55. Global Suvorexant API Sales Market Share in Value by Application (2021–2026)
 Table 56. Global Suvorexant API Sales Market Share in Value by Application (2027–2032)
 Table 57. Global Suvorexant API Sales Volume by Application: 2021 vs 2025 vs 2032 (kg)
 Table 58. Global Suvorexant API Sales Volume by Application (kg), 2021–2026
 Table 59. Global Suvorexant API Sales Volume by Application (kg), 2027–2032
 Table 60. Global Suvorexant API Sales Market Share in Volume by Application (2021–2026)
 Table 61. Global Suvorexant API Sales Market Share in Volume by Application (2027–2032)
 Table 62. Global Suvorexant API Price by Application (US$/kg), 2021–2026
 Table 63. Global Suvorexant API Price by Application (US$/kg), 2027–2032
 Table 64. Global Suvorexant API Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
 Table 65. Global Suvorexant API Sales Value by Region (US$ Million), 2021–2026
 Table 66. Global Suvorexant API Sales Value by Region (US$ Million), 2027–2032
 Table 67. Global Suvorexant API Sales Value by Region (%), 2021–2026
 Table 68. Global Suvorexant API Sales Value by Region (%), 2027–2032
 Table 69. Global Suvorexant API Sales Volume by Region (kg): 2021 vs 2025 vs 2032
 Table 70. Global Suvorexant API Sales Volume by Region (kg), 2021–2026
 Table 71. Global Suvorexant API Sales Volume by Region (kg), 2027–2032
 Table 72. Global Suvorexant API Sales Volume by Region (%), 2021–2026
 Table 73. Global Suvorexant API Sales Volume by Region (%), 2027–2032
 Table 74. Global Suvorexant API Average Price by Region (US$/kg), 2021–2026
 Table 75. Global Suvorexant API Average Price by Region (US$/kg), 2027–2032
 Table 76. Key Countries/Regions Suvorexant API Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
 Table 77. Key Countries/Regions Suvorexant API Sales Value, (US$ Million), 2021–2026
 Table 78. Key Countries/Regions Suvorexant API Sales Value, (US$ Million), 2027–2032
 Table 79. Key Countries/Regions Suvorexant API Sales Volume, (kg), 2021–2026
 Table 80. Key Countries/Regions Suvorexant API Sales Volume, (kg), 2027–2032
 Table 81. Merck Company Information
 Table 82. Merck Introduction and Business Overview
 Table 83. Merck Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 84. Merck Suvorexant API Product Offerings
 Table 85. Merck Recent Developments
 Table 86. Biophore Company Information
 Table 87. Biophore Introduction and Business Overview
 Table 88. Biophore Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 89. Biophore Suvorexant API Product Offerings
 Table 90. Biophore Recent Developments
 Table 91. Metrochem Company Information
 Table 92. Metrochem Introduction and Business Overview
 Table 93. Metrochem Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 94. Metrochem Suvorexant API Product Offerings
 Table 95. Metrochem Recent Developments
 Table 96. Alembic Pharmaceuticals Company Information
 Table 97. Alembic Pharmaceuticals Introduction and Business Overview
 Table 98. Alembic Pharmaceuticals Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 99. Alembic Pharmaceuticals Suvorexant API Product Offerings
 Table 100. Alembic Pharmaceuticals Recent Developments
 Table 101. Bajaj Healthcare Company Information
 Table 102. Bajaj Healthcare Introduction and Business Overview
 Table 103. Bajaj Healthcare Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 104. Bajaj Healthcare Suvorexant API Product Offerings
 Table 105. Bajaj Healthcare Recent Developments
 Table 106. DEAFARMA Company Information
 Table 107. DEAFARMA Introduction and Business Overview
 Table 108. DEAFARMA Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 109. DEAFARMA Suvorexant API Product Offerings
 Table 110. DEAFARMA Recent Developments
 Table 111. LifeFirst Pharma Company Information
 Table 112. LifeFirst Pharma Introduction and Business Overview
 Table 113. LifeFirst Pharma Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 114. LifeFirst Pharma Suvorexant API Product Offerings
 Table 115. LifeFirst Pharma Recent Developments
 Table 116. Saptagir Laboratories Company Information
 Table 117. Saptagir Laboratories Introduction and Business Overview
 Table 118. Saptagir Laboratories Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 119. Saptagir Laboratories Suvorexant API Product Offerings
 Table 120. Saptagir Laboratories Recent Developments
 Table 121. SMS Pharmaceuticals Company Information
 Table 122. SMS Pharmaceuticals Introduction and Business Overview
 Table 123. SMS Pharmaceuticals Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 124. SMS Pharmaceuticals Suvorexant API Product Offerings
 Table 125. SMS Pharmaceuticals Recent Developments
 Table 126. Viatris Company Information
 Table 127. Viatris Introduction and Business Overview
 Table 128. Viatris Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 129. Viatris Suvorexant API Product Offerings
 Table 130. Viatris Recent Developments
 Table 131. Zydus Lifesciences Company Information
 Table 132. Zydus Lifesciences Introduction and Business Overview
 Table 133. Zydus Lifesciences Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 134. Zydus Lifesciences Suvorexant API Product Offerings
 Table 135. Zydus Lifesciences Recent Developments
 Table 136. Axplora Company Information
 Table 137. Axplora Introduction and Business Overview
 Table 138. Axplora Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 139. Axplora Suvorexant API Product Offerings
 Table 140. Axplora Recent Developments
 Table 141. Apino Pharma Company Information
 Table 142. Apino Pharma Introduction and Business Overview
 Table 143. Apino Pharma Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 144. Apino Pharma Suvorexant API Product Offerings
 Table 145. Apino Pharma Recent Developments
 Table 146. Conscientia Industrial Company Information
 Table 147. Conscientia Industrial Introduction and Business Overview
 Table 148. Conscientia Industrial Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 149. Conscientia Industrial Suvorexant API Product Offerings
 Table 150. Conscientia Industrial Recent Developments
 Table 151. BSAZ Biotech Company Information
 Table 152. BSAZ Biotech Introduction and Business Overview
 Table 153. BSAZ Biotech Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 154. BSAZ Biotech Suvorexant API Product Offerings
 Table 155. BSAZ Biotech Recent Developments
 Table 156. Sandoo Pharmaceutical Company Information
 Table 157. Sandoo Pharmaceutical Introduction and Business Overview
 Table 158. Sandoo Pharmaceutical Suvorexant API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021–2026)
 Table 159. Sandoo Pharmaceutical Suvorexant API Product Offerings
 Table 160. Sandoo Pharmaceutical Recent Developments
 Table 161. Key Raw Materials Lists
 Table 162. Key Suppliers of Raw Materials Lists
 Table 163. Suvorexant API Downstream Customers
 Table 164. Suvorexant API Distributors List
 Table 165. Research Programs/Design for This Report
 Table 166. Key Data Information from Secondary Sources
 Table 167. Key Data Information from Primary Sources


List of Figures
 Figure 1. Suvorexant API Product Picture
 Figure 2. Global Suvorexant API Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 3. Global Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 4. Global Suvorexant API Sales Volume (kg), 2021–2032
 Figure 5. Global Suvorexant API Sales Price (US$/kg), 2021–2032
 Figure 6. Suvorexant API Report Years Considered
 Figure 7. Global Suvorexant API Players Revenue Ranking (US$ Million), 2025
 Figure 8. Global Suvorexant API Sales Volume Ranking of Players (kg), 2025
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Suvorexant API Revenue in 2025
 Figure 10. Suvorexant API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 11. Industrial Grade (98%-99.0%) Picture
 Figure 12. Pharmaceutical Grade (99.0%-99.5%) Picture
 Figure 13. High Purity Grade (Greater Than 99.5%) Picture
 Figure 14. Global Suvorexant API Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Suvorexant API Sales Value Market Share by Type, 2025 & 2032
 Figure 16. Global Suvorexant API Sales Volume by Type (kg), 2021 vs 2025 vs 2032
 Figure 17. Global Suvorexant API Sales Volume Market Share by Type, 2025 & 2032
 Figure 18. Global Suvorexant API Price by Type (US$/kg), 2021–2032
 Figure 19. Fragment Splicing Method Picture
 Figure 20. Linear Synthesis Method Picture
 Figure 21. Global Suvorexant API Sales Value by Synthesis Method (US$ Million), 2021 vs 2025 vs 2032
 Figure 22. Global Suvorexant API Sales Value Market Share by Synthesis Method, 2025 & 2032
 Figure 23. Global Suvorexant API Sales Volume by Synthesis Method (kg), 2021 vs 2025 vs 2032
 Figure 24. Global Suvorexant API Sales Volume Market Share by Synthesis Method, 2025 & 2032
 Figure 25. Global Suvorexant API Price by Synthesis Method (US$/kg), 2021–2032
 Figure 26. Original Drug Picture
 Figure 27. Generic Drug Picture
 Figure 28. Global Suvorexant API Sales Value by Drug Registration Classification (US$ Million), 2021 vs 2025 vs 2032
 Figure 29. Global Suvorexant API Sales Value Market Share by Drug Registration Classification, 2025 & 2032
 Figure 30. Global Suvorexant API Sales Volume by Drug Registration Classification (kg), 2021 vs 2025 vs 2032
 Figure 31. Global Suvorexant API Sales Volume Market Share by Drug Registration Classification, 2025 & 2032
 Figure 32. Global Suvorexant API Price by Drug Registration Classification (US$/kg), 2021–2032
 Figure 33. Product Picture of Insomnia
 Figure 34. Product Picture of Others
 Figure 35. Global Suvorexant API Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
 Figure 36. Global Suvorexant API Sales Value Market Share by Application, 2025 & 2032
 Figure 37. Global Suvorexant API Sales Volume by Application (kg), 2021 vs 2025 vs 2032
 Figure 38. Global Suvorexant API Sales Volume Market Share by Application, 2025 & 2032
 Figure 39. Global Suvorexant API Price by Application (US$/kg), 2021–2032
 Figure 40. North America Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 41. North America Suvorexant API Sales Value by Country (%), 2025 vs 2032
 Figure 42. Europe Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 43. Europe Suvorexant API Sales Value by Country (%), 2025 vs 2032
 Figure 44. Asia Pacific Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 45. Asia Pacific Suvorexant API Sales Value by Region (%), 2025 vs 2032
 Figure 46. South America Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 47. South America Suvorexant API Sales Value by Country (%), 2025 vs 2032
 Figure 48. Middle East & Africa Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 49. Middle East & Africa Suvorexant API Sales Value by Country (%), 2025 vs 2032
 Figure 50. Key Countries/Regions Suvorexant API Sales Value (%), 2021–2032
 Figure 51. Key Countries/Regions Suvorexant API Sales Volume (%), 2021–2032
 Figure 52. United States Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 53. United States Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 54. United States Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 55. Europe Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 56. Europe Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 57. Europe Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 58. China Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 59. China Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 60. China Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 61. Japan Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 62. Japan Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 63. Japan Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 64. South Korea Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 65. South Korea Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 66. South Korea Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 67. Southeast Asia Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 68. Southeast Asia Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 69. Southeast Asia Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 70. India Suvorexant API Sales Value (US$ Million), 2021–2032
 Figure 71. India Suvorexant API Sales Value by Type (%), 2025 vs 2032
 Figure 72. India Suvorexant API Sales Value by Application (%), 2025 vs 2032
 Figure 73. Suvorexant API Industrial Chain
 Figure 74. Suvorexant API Manufacturing Cost Structure
 Figure 75. Channels of Distribution (Direct Sales, and Distribution)
 Figure 76. Bottom-up and Top-down Approaches for This Report
 Figure 77. Data Triangulation
 Figure 78. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有